Literature DB >> 8097042

Fetal behavior and the dopamine system: activity effects of D1 and D2 receptor manipulations.

C A Moody1, S R Robinson, L P Spear, W P Smotherman.   

Abstract

Binding studies have indicated that D1 and D2 dopamine receptor subtypes are present in rats before birth, but it is not known whether these receptors are functional during the prenatal period. In the present study, day-21 rat fetuses were prepared for direct observation after pharmacological manipulation of D1 and/or D2 receptors. The D1 agonist SK&F38393 induced a marked increase in fetal activity (i.e., forelimb, rearlimb, and head movements) while the D2 agonist quinpirole produced a slight suppression in activity. Coadministration of both agonists resulted in low levels of fetal activity, suggesting an interaction between D1 and D2 receptors. Administration of the D2 antagonist sulpiride resulted in little change in fetal behavior but was effective in blocking the behavioral activation induced by the D1 agonist. The D1 antagonist SCH23390, administered alone or in combination with the D2 antagonist, produced a modest increase in fetal activity that included mouthing and facial wiping behavior. These data provide evidence that the dopamine system is functional and capable of mediating behavioral effects in the near-term rat fetus. Further, manipulation of dopamine receptors results in a different pattern of behavioral effects than has been reported in older animals. The observation that fetal behavior is influenced by these pharmacological challenges suggests that drugs of abuse known to affect the dopamine system, such as cocaine, may cause profound changes in fetal behavior in utero that could consequently lead to alterations in behavioral and CNS development.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097042     DOI: 10.1016/0091-3057(93)90015-l

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  L-dopa reverses behavioral deficits in the Pitx3 mouse fetus.

Authors:  Gale A Kleven; Heather M Booth; Marco Voogd; April E Ronca
Journal:  Behav Neurosci       Date:  2014-08-25       Impact factor: 1.912

2.  The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Authors:  Sanders A McDougall; Rita M Hernandez; Carmela M Reichel; Cristal M Farley
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

3.  In utero cocaine-induced dysfunction of dopamine D1 receptor signaling and abnormal differentiation of cerebral cortical neurons.

Authors:  L B Jones; G D Stanwood; B S Reinoso; R A Washington; H Y Wang; E Friedman; P Levitt
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

4.  In utero exposure to antipsychotic medication and psychiatric outcomes in the offspring.

Authors:  Veerle Bergink; Trine Munk-Olsen; Natalie C Momen; Thalia Robakis; Xiaoqin Liu; Abraham Reichenberg
Journal:  Neuropsychopharmacology       Date:  2021-11-08       Impact factor: 7.853

5.  Prenatal ontogeny of the dopamine-dependent neurobehavioral phenotype in Pitx3-deficient mice.

Authors:  Gale A Kleven; Priyanka Joshi; Marco Voogd; April E Ronca
Journal:  Eur J Neurosci       Date:  2013-03-13       Impact factor: 3.386

6.  Dopamine receptors modulate ethanol's locomotor-activating effects in preweanling rats.

Authors:  Carlos Arias; Estela C Mlewski; Cristian Hansen; Juan Carlos Molina; Maria Gabriela Paglini; Norman E Spear
Journal:  Dev Psychobiol       Date:  2010-01       Impact factor: 3.038

7.  Effect of betamethasone on the expression of dopamine D1 receptor mRNA in the developing rabbit adrenal gland.

Authors:  Jean-Marc Labaune; Marie-Jeanne Boutroy; Aida Bairam
Journal:  Curr Ther Res Clin Exp       Date:  2003-09

8.  Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats.

Authors:  Jenny L Wiley
Journal:  Eur J Pharmacol       Date:  2007-09-26       Impact factor: 4.432

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.